Gottfried Konecny, M.D.
Research performed at: UCLA's Jonsson Comprehensive Cancer Center
Specialty/Research Area: Gynecologic Oncology, Breast Cancer
Career Summary: Gottfried E. Konecny is Associate Professor of Medicine at UCLA. He is the lead clinician for gynecologic oncology in the Department of Medicine at UCLA. He obtained his medical degree and completed his residency training in obstetrics and gynecology at the University of Munich in Germany. Following his specialist training he focused on clinical breast cancer research and decided to move to the US to pursue postdoctoral studies in the laboratory of Dennis J. Slamon to participate in laboratory and clinical research that led to the approval of new breast cancer drugs such as trastuzumab and lapatinib. He subsequently undertook research and subspecialty training in gynecologic oncology by completing a gynecologic oncology fellowship at Mayo Clinic in Rochester Minnesota. In 2007 he was recruited back to UCLA as a group leader to the Translational Oncology Research Laboratory of UCLA, to establish a program for preclinical drug and clinical trial development in the area of gynecologic malignancies.
Year STOP CANCER Award is being received: 2017 Shirley McKernan & Joan Feldman Seed Grant
Description of research performed: His initiatives are primarily directed at using the latest and most effective technologies available to query breast, ovarian and endometrial cancer tissues, combined with appropriately characterized and molecularly defined preclinical models to identify new alterations and/or understand the role of known alterations in relevant genes and molecular pathways. His work primarily aims to identify physiologically distinct disease subgroups with their dominant signaling pathways and signaling alterations to develop subtype-specific novel treatment approaches for patients diagnosed with breast, ovarian or endometrial cancer. Results of research: As a physician-scientist his work focuses on translating the incredible revolution in our understanding of the molecular underpinnings of cancer into novel treatment approaches, in which each patient is treated according to the specific genetic alterations of the tumor. His recent translational efforts have focused on the development of new treatments for patients diagnosed with ovarian or endometrial cancer including novel drugs targeting IGFR1, FGFR2, CDK4/6, PARP, p53 and PD1.